Cargando…
Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy
INTRODUCTION: Sjögren's syndrome (SjS) is a systemic autoimmune disease characterized by decreased salivary and lacrimal gland secretions, resulting in severe dry mouth and dry eyes. Recent studies have suggested that T(H)17 cells and its signature cytokine IL-17 are involved in the underlying...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580566/ https://www.ncbi.nlm.nih.gov/pubmed/22827855 http://dx.doi.org/10.1186/ar3925 |
_version_ | 1782260278201679872 |
---|---|
author | Lee, Byung Ha Carcamo, Wendy C Chiorini, John A Peck, Ammon B Nguyen, Cuong Q |
author_facet | Lee, Byung Ha Carcamo, Wendy C Chiorini, John A Peck, Ammon B Nguyen, Cuong Q |
author_sort | Lee, Byung Ha |
collection | PubMed |
description | INTRODUCTION: Sjögren's syndrome (SjS) is a systemic autoimmune disease characterized by decreased salivary and lacrimal gland secretions, resulting in severe dry mouth and dry eyes. Recent studies have suggested that T(H)17 cells and its signature cytokine IL-17 are involved in the underlying pathogenic mechanisms leading to destructive inflammation and autoimmunity. In the present study, we examined whether IL-27, a natural inhibitor of T(H)17 activity, could down-regulate or reverse SjS in C57BL/6.NOD-Aec1Aec2 mice, a model of primary-SjS. METHODS: Recombinant serotype 2 adeno-associated viral (AAV2) vectors expressing either IL-27 (rAAV2-IL27) or LacZ (rAAV2-LacZ) were injected into 6 or 14 week-old C57BL/6.NOD-Aec1Aec2 mice. Changes in IL-27, IL-17, and IL-10 cytokine levels in peripheral blood were determined by ELISAs, while flow cytometry analyses were used to quantify cytokine-positive splenocytes. Histological assessment of salivary glands, anti-nuclear autoantibody (ANA) staining, and stimulated saliva flow rates were used to profile SjS disease severity. RESULTS: Mice systemically treated with intravenous rAAV2-IL27 injections at either 6 or 14 weeks of age exhibited long-term elevated levels of serum IL-27 with concomitantly reduced levels of IL-17 compared with sera from mice injected with rAAV2-LacZ or saline out to 20 weeks post-inoculation. Most importantly, disease profiles revealed that rAAV2-IL27 treatment had little effect on lymphocytic focus (LF) scores, but resulted in structural changes in LF, lower titers of ANAs with changes in staining patterns, and a less severe clinical disease as determined by saliva flow rates. CONCLUSIONS: These data support the concept that IL-27, when provided exogenously, can induce a suppressive effect on SjS development and thus may be an effective therapeutic agent for regulating T(H)17 pro-inflammatory activity in autoimmune diseases where the T(H)17 system has been shown to play an important role in their pathogenesis. |
format | Online Article Text |
id | pubmed-3580566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35805662013-02-26 Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy Lee, Byung Ha Carcamo, Wendy C Chiorini, John A Peck, Ammon B Nguyen, Cuong Q Arthritis Res Ther Research Article INTRODUCTION: Sjögren's syndrome (SjS) is a systemic autoimmune disease characterized by decreased salivary and lacrimal gland secretions, resulting in severe dry mouth and dry eyes. Recent studies have suggested that T(H)17 cells and its signature cytokine IL-17 are involved in the underlying pathogenic mechanisms leading to destructive inflammation and autoimmunity. In the present study, we examined whether IL-27, a natural inhibitor of T(H)17 activity, could down-regulate or reverse SjS in C57BL/6.NOD-Aec1Aec2 mice, a model of primary-SjS. METHODS: Recombinant serotype 2 adeno-associated viral (AAV2) vectors expressing either IL-27 (rAAV2-IL27) or LacZ (rAAV2-LacZ) were injected into 6 or 14 week-old C57BL/6.NOD-Aec1Aec2 mice. Changes in IL-27, IL-17, and IL-10 cytokine levels in peripheral blood were determined by ELISAs, while flow cytometry analyses were used to quantify cytokine-positive splenocytes. Histological assessment of salivary glands, anti-nuclear autoantibody (ANA) staining, and stimulated saliva flow rates were used to profile SjS disease severity. RESULTS: Mice systemically treated with intravenous rAAV2-IL27 injections at either 6 or 14 weeks of age exhibited long-term elevated levels of serum IL-27 with concomitantly reduced levels of IL-17 compared with sera from mice injected with rAAV2-LacZ or saline out to 20 weeks post-inoculation. Most importantly, disease profiles revealed that rAAV2-IL27 treatment had little effect on lymphocytic focus (LF) scores, but resulted in structural changes in LF, lower titers of ANAs with changes in staining patterns, and a less severe clinical disease as determined by saliva flow rates. CONCLUSIONS: These data support the concept that IL-27, when provided exogenously, can induce a suppressive effect on SjS development and thus may be an effective therapeutic agent for regulating T(H)17 pro-inflammatory activity in autoimmune diseases where the T(H)17 system has been shown to play an important role in their pathogenesis. BioMed Central 2012 2012-07-24 /pmc/articles/PMC3580566/ /pubmed/22827855 http://dx.doi.org/10.1186/ar3925 Text en Copyright ©2012 Lee et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Lee, Byung Ha Carcamo, Wendy C Chiorini, John A Peck, Ammon B Nguyen, Cuong Q Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy |
title | Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy |
title_full | Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy |
title_fullStr | Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy |
title_full_unstemmed | Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy |
title_short | Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy |
title_sort | gene therapy using il-27 ameliorates sjögren's syndrome-like autoimmune exocrinopathy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580566/ https://www.ncbi.nlm.nih.gov/pubmed/22827855 http://dx.doi.org/10.1186/ar3925 |
work_keys_str_mv | AT leebyungha genetherapyusingil27amelioratessjogrenssyndromelikeautoimmuneexocrinopathy AT carcamowendyc genetherapyusingil27amelioratessjogrenssyndromelikeautoimmuneexocrinopathy AT chiorinijohna genetherapyusingil27amelioratessjogrenssyndromelikeautoimmuneexocrinopathy AT peckammonb genetherapyusingil27amelioratessjogrenssyndromelikeautoimmuneexocrinopathy AT nguyencuongq genetherapyusingil27amelioratessjogrenssyndromelikeautoimmuneexocrinopathy |